Equities

Beauty Health Co

Beauty Health Co

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (USD)1.53
  • Today's Change0.02 / 1.32%
  • Shares traded602.03k
  • 1 Year change-74.71%
  • Beta0.9775
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold7
Sell3
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Beauty Health Co have a median target of 2.00, with a high estimate of 10.50 and a low estimate of 1.00. The median estimate represents a 32.45% increase from the last price of 1.51.
High595.4%10.50
Med32.5%2.00
Low-33.8%1.00

Earnings history & estimates in USD

On Aug 08, 2024, Beauty Health Co reported 2nd quarter 2024 breakeven earnings per share. This result exceeded the -0.05 consensus loss of the 9 analysts covering the company and under-performed last year's 2nd quarter results by 96.67%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+86.82%
Beauty Health Co reported annual 2023 losses of -0.76 per share on Mar 12, 2024.
More ▼

Revenue history & estimates in USD

Beauty Health Co had 2nd quarter 2024 revenues of 90.60m. This missed the 98.51m consensus estimate of the 10 analysts following the company. This was 4.98% above the prior year's 2nd quarter results.
Average growth rate-5.58%
Beauty Health Co had revenues for the full year 2023 of 398.00m. This was 8.77% above the prior year's results.
Average growth rate+24.73%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.